WO2020171649A1 - Combinaison pharmaceutique comprenant un inhibiteur flt3 et un antagoniste iap pour le traitement de la leucémie myéloïde aiguë - Google Patents

Combinaison pharmaceutique comprenant un inhibiteur flt3 et un antagoniste iap pour le traitement de la leucémie myéloïde aiguë Download PDF

Info

Publication number
WO2020171649A1
WO2020171649A1 PCT/KR2020/002541 KR2020002541W WO2020171649A1 WO 2020171649 A1 WO2020171649 A1 WO 2020171649A1 KR 2020002541 W KR2020002541 W KR 2020002541W WO 2020171649 A1 WO2020171649 A1 WO 2020171649A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
chloro
cyclopropyl
indol
alkyl
Prior art date
Application number
PCT/KR2020/002541
Other languages
English (en)
Korean (ko)
Inventor
배인환
송지영
최재율
안영길
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority claimed from KR1020200021501A external-priority patent/KR20200102948A/ko
Publication of WO2020171649A1 publication Critical patent/WO2020171649A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention is a treatment of acute myeloid leukemia comprising a therapeutically effective combination of an Fms-Like Tyrosine kinase-3 (FLT3) inhibitor and an inhibitor of apoptosis protein (IAP) antagonist It relates to a pharmaceutical combination for and a method of treating acute myeloid leukemia using the same.
  • FLT3 Fms-Like Tyrosine kinase-3
  • IAP apoptosis protein
  • Fms-Like Tyrosine kinase-3 is one of the most frequently mutated genes in acute myeloid leukemia (AML).
  • Mutant FLT3 refers to a mutation expressed in leukemia cells in a subpopulation of patients with acute myelogenous leukemia (AML).
  • Activation mutations in FLT3 such as internal tandem duplication (ITD) in the membranous domain appear to be about 25 to 30 in AML cases that are newly diagnosed (Patent Document 1). It is known that the FLT3 mutation occurs in about one third of patients with acute myeloid leukemia (AML) (Non-Patent Document 1).
  • Non-Patent Document 1 There are several FLT3 inhibitors that can be used clinically, but drug-resistant leukocyte cells were observed in AML patients treated with these FLT3 inhibitors and showed drug resistance (Non-Patent Document 1).
  • conventional standard chemotherapy for acute myelogenous leukemia (AML) cannot target AML stem/progenitor cells, so the disease frequently recurs in patients, thereby limiting long-term efficacy. Yes (Non-Patent Document 2). Therefore, there is a need for a method that can effectively treat mutant acute leukemia patients.
  • Non-Patent Document 3 Inhibitor of apoptosis protein (IAP) antagonists are proteins that play a role in mediating apoptosis, and these proteins are variously expressed in acute leukemia, chemosensitivity, and chemoresistance. ), disease progression, remission, and patient survival (Non-Patent Document 3).
  • a treatment method for acute myeloid leukemia (AML) and hematologic malignancies in combination with an IAP antagonist and an FLT3 inhibitor was studied (Patent Document 3).
  • Patent Document 2 is a quinoline or a quinazoline derivative, such as "(S)-N-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yl)-1 IAP antagonists such as "((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide hydrochloride”
  • IAP apoptosis inhibitory protein
  • Patent Document 1 Korean Patent Application Publication No. 10-2018-0124055
  • Patent Document 2 Korean Patent Registration No. 10-1560227
  • Patent Document 3 Korean Laid-Open Patent No. 10-2009-0087094
  • Non-Patent Document 2 J Natl Cancer Inst. Vol. 106, Issue 2, djt440, February 5, 2014
  • the present invention can lead to better therapeutic outcomes by providing an alternative therapy for the treatment of AML, including patients with FLT3 mutations.
  • FLT3 is a promising therapeutic target for leukemia and is mutated in approximately 30% or more of AML patients.
  • AML patients there is increasing interest in the occurrence and refractory of drug resistance resulting from the appearance of point mutations in targeted tyrosine kinases used for the treatment of patients with acute leukemia.
  • One approach to overcoming this resistance is confirmed by determining whether the efficacy and therapeutic effect are enhanced by combining inhibitors that are not structurally related and/or inhibitors of different signaling pathways.
  • One aspect of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor, a pharmaceutically acceptable salt thereof, or a solvate thereof, apoptosis inhibitory protein (inhibitor It provides a pharmaceutical composition for the treatment of acute myelogenous leukemia (AML), characterized in that it is administered in combination with an antagonist, a pharmaceutically acceptable salt thereof, or a solvate of apoptosis protein: IAP.
  • FLT3 Fms-like tyrosine kinase-3
  • IAP apoptosis inhibitory protein
  • Another aspect of the present invention provides a pharmaceutical kit, wherein the pharmaceutical compositions are administered simultaneously, sequentially, in reverse order or separately.
  • Another aspect of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising an inhibitor of apoptosis protein (IAP) antagonist, or a pharmaceutically acceptable salt or solvate thereof, Fms-like tyrosine kinase (FLT3 )
  • IAP apoptosis protein
  • FLT3 Fms-like tyrosine kinase
  • One aspect of the present invention provides a pharmaceutical composition of an Fms-like tyrosine kinase (FLT3) inhibitor and an apoptosis inhibitory protein (IAP) antagonist, and a kit or combination comprising the combination.
  • FLT3 Fms-like tyrosine kinase
  • IAP apoptosis inhibitory protein
  • One aspect of the present invention provides a method of treating hematologic malignancies including acute myeloid leukemia (AML) using the pharmaceutical combination, kit or composition, and the use of these combinations for the treatment of acute myeloid leukemia.
  • AML acute myeloid leukemia
  • One aspect of the present invention can increase the therapeutic effect of AML, including patients with FLT3 mutations, by providing the pharmaceutical combination, kit or composition.
  • FIG. 1 shows the degree of inhibition of MOLM-13 cell growth by a combination treatment of Compound A and azacytidine.
  • the Y-axis represents the cell growth rate (%), and the X-axis represents the logarithmic concentration of Compound A (the logarithmic value of the concentration in nM).
  • the Y axis represents the cell growth rate (%) and the X axis represents each experimental group.
  • FIG. 3 shows the antitumor effect when compound A and azacytidine were administered in combination in nude mice xenografted with MOLM-13-Luc2 cell line.
  • the Y axis represents the percentage of surviving mice in each experimental group (survival rate) (%), and the X axis represents the number of days of administration.
  • FLT3 Fms-like tyrosine kinase-3
  • IAP inhibitor of apoptosis protein
  • Acute myelogenous leukemia as used herein includes acute myelogenous leukemia with FLT3 mutation.
  • the acute myelogenous leukemia comprises mutant FLT3 polynucleotide-positive myelogenous leukemia, columnar overlap in the FLT3 gene (ITD) positive acute myelogenous leukemia, or acute myelogenous leukemia with a FLT3 point mutation.
  • FLT3 is a member of the class III receptor tyrosine kinase (TK) family that is normally expressed on the surface of hematopoietic stem cells. FLT3 and its ligands play an important role in the proliferation, survival and differentiation of pluripotent stem cells. FLT3 is expressed in a number of AML cases.
  • activated FLT3 with intragene columnar overlap (ITD) in and around the membranous domain and tyrosine kinase domain (TKD) mutations near D835 in the activation loop were between 28% and 34% and 11% of AML cases, respectively. It is present at 14%. These activated mutations in FLT3 are tumorigenic and exhibit modifying activity in cells.
  • the FLT3 inhibitor is 4'-N-benzoylstaurosporine (ingredient name: midostaurin), 6-ethyl-3-[[3-methoxy-4-[4-(4] -Methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide (ingredient name: Giltary Tinib, gilteritinib), 1-(2- ⁇ 5-[(3-methoxaten-3-l)methoxy]-1H-benzimidazol-1-yl ⁇ quinolin-8-yl)piperidine-4 -Amine (ingredient name: Crenolanib, Crenolanib), 1-(5-(tert-butyl)isooxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benz
  • any pharmaceutically acceptable salt or hydrate form of the FLT3 inhibitor but is not limited to these substances.
  • the FLT3 inhibitor is a compound having kinase inhibitory activity described in International Patent Application Publication No. WO2018-139903, or a compound having FLT3 inhibitory activity described in Korean Patent Application Application No. 10-2018-0086768, or It may be any pharmaceutically acceptable salt or hydrate.
  • One aspect of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor, a pharmaceutically acceptable salt thereof, or a solvate thereof, an IAP antagonist, a pharmaceutical composition thereof It is administered in combination with an acceptable salt or solvate, wherein the FLT3 inhibitor is a compound selected from a compound of Formula 1, a stereoisomer thereof, a tautomer, and a combination thereof, a pharmaceutical for the treatment of acute myelogenous leukemia (AML) Provide the appropriate composition.
  • FLT3 Fms-like tyrosine kinase-3
  • E a is hydrogen, hydroxy or C 1-4 alkoxy
  • E b is hydrogen, halogen, C 1-4 alkyl or C 1-4 fluoroalkyl
  • E c and E d are independently of each other hydrogen or hydroxy
  • X' is hydrogen or hydroxy
  • k is an integer from 1 to 2;
  • Each Q is independently of each other hydroxy, halogen, C 1-4 alkyl, hydroxyC 1-4 alkyl or C 1-4 alkoxy;
  • Z' is a monovalent functional group shown in Formula 2;
  • n is an integer of 1 to 2;
  • Each A is independently from each other a functional group selected from hydroxy, C 1-4 alkyl and hydroxyC 1-4 alkyl, wherein at least one A is C 1-4 alkyl;
  • L is hydrogen, C 1-4 alkyl, hydroxy or hydroxyC 1-4 alkyl.
  • solvate refers to a molecular complex of a compound of the present invention (or a pharmaceutically acceptable salt thereof) and one or more solvent molecules.
  • solvent molecules may be those known or commonly used in the pharmaceutical art, such as water, ethanol, and the like.
  • hydrate refers to a complex in which the solvent molecule is water.
  • salt or “pharmaceutically acceptable salt” as used herein refers to a pharmaceutically acceptable derivative of the disclosed compound, wherein the parent compound is by converting an acid or base moiety present into its salt form Denatured.
  • the FLT3 inhibitor may be a compound selected from a compound represented by Formula 3 below, a stereoisomer thereof, a tautomer, and a combination thereof.
  • E f is fluorine, chlorine, bromine or iodine
  • Q o is hydroxy, halogen, C 1-4 alkyl, hydroxyC 1-4 alkyl or C 1-4 alkoxy;
  • s is an integer from 1 to 2;
  • a o is a functional group selected from hydroxy, C 1-4 alkyl and hydroxyC 1-4 alkyl;
  • t is an integer of 1 to 2.
  • the FLT3 inhibitor may be a compound having kinase inhibitory activity described in International Patent Application Publication No. WO2018-139903, for example, a compound selected from the group consisting of compounds listed in Nos. 1 to 55 of Table 1 below. , Or any pharmaceutically acceptable salt or hydrate thereof.
  • the FLT3 inhibitor may be a compound having FLT3 inhibitory activity described in Korean Patent Application No. 10-2018-0086768, for example, in the group consisting of the compounds listed in Table 2 below. It may be a selected compound, or a compound selected from the group consisting of any pharmaceutically acceptable salt or hydrate thereof.
  • the FLT3 inhibitor is 5-chloro-N-(3-cyclopropyl-5-(((3R, 5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-( 6-methyl-1H-indol-3-yl)pyrimidin-2-amine, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
  • the inhibitor of apoptosis protein refers to a protein that binds to and neutralizes the cysteine protease series caspase involved in cell death. Amplification of the IAP gene and overexpression of IAP are found in many tumor cells.
  • an antagonist in a broad sense, for example, any substance that partially or completely inhibits or neutralizes the biological activity of the polypeptide, or partially or completely inhibits the transcription or translation of the nucleic acid encoding the polypeptide. Include.
  • the IAP antagonist is (3S,3'S,6S,6'S,10aS,10a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(butane-4,1-diyl) )Bis(1H-1,2,3-triazole-1,4-diyl))bis(phenylmethylene))bis(6-((S)-2-(methylamino)propanamido)-5-oxo Decahydropyrrolo[1,2-a]azosine-3-carboxamide) (AT-406), (S)-N-((S)-1-cyclohexyl-2-((S)-2 -(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide (LCL-161), (S)- N-((S)-1-cyclohexy
  • any pharmaceutically acceptable salts or hydrates thereof of IAP antagonists but is not limited to these substances.
  • the IAP antagonist is a compound having IAP inhibitory activity described in Korean Patent Application Publication No. 10-2013-0121092 or International Patent Application Publication No. WO2012-030160, more specifically, quinoline of the following formula 4 or It may be a compound selected from the group consisting of quinazoline derivatives, and salts, isomers, hydrates and solvates thereof.
  • Z is CH or N
  • n is an integer from 0 to 3;
  • R 1 is hydrogen, C 1-6 alkyl, C 1-6 alkanoyl, C 2-6 alkenoyl or C 2-6 alkinoyl;
  • R 2 is hydrogen or C 1-3 alkyl
  • R 3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl or C 3-6 alkynyloxyC 1-4 alkyl;
  • R 4 and R 5 are each independently hydrogen, or -O(CH 2 ) m -C 1-6 alkyl, -O(CH 2 ) m -C 3-6 cycloalkyl, -O(CH 2 ) m -C 3-6 heterocycloalkyl, -O(CH 2 ) m -C 5-10 aryl, -O(CH 2 ) m -C 5-10 heteroaryl or -O(CH 2 ) m -C 1-3 alkoxy, and , Where m is an integer of 0 to 3;
  • R 6 is hydrogen or C 1-6 alkyl
  • R 7 is hydrogen, C 1-8 alkyl, or -(CH 2 ) l -C 3-6 cycloalkyl, -(CH 2 ) l -C 3-6 heterocycloalkyl, -(CH 2 ) l -C 5 -10 aryl or -(CH 2 ) l -C 5-10 heteroaryl, where l is an integer from 0 to 3;
  • the R 6 and R 7 may be optionally linked to each other to form a ring structure
  • the R 8 , R 9 , R 10 , R 11 and R 12 are each independently halogen, -CF 3 , -NO 2 , -CN, C 1-6 alkyl, and -(CH 2 ) q -C 3-6 Cycloalkyl, -(CH 2 ) q -C 3-6 heterocycloalkyl, -(CH 2 ) q -C 2-4 alkenyl, -(CH 2 ) q -C 2-4 alkynyl, -(CH 2 ) q -C 5-10 aryl or -(CH 2 ) q -C 5-10 heteroaryl, where q is an integer from 0 to 3;
  • the R 8 and R 9 may be selectively linked to each other to form a ring structure.
  • the IAP antagonist is in Formula 4,
  • Y is -NR 6 R 7 ;
  • n 1;
  • R 1 is hydrogen or C 1-6 alkyl
  • R 2 is hydrogen or C 1-3 alkyl
  • R 3 is hydrogen or C 1-6 alkyl
  • R 4 and R 5 are each independently hydrogen or -O(CH 2 ) m -C 1-6 alkyl, where m is an integer from 0 to 3;
  • R 6 is hydrogen or C 1-6 alkyl
  • R 7 is hydrogen, C 1-8 alkyl, or -(CH 2 ) l -C 3-6 cycloalkyl, where l is an integer from 0 to 3;
  • R 7 may be optionally substituted with one or more substituents selected from the group consisting of halogen, -CF 3 , -NO 2 , -CN, and C 1-8 alkyl.
  • the IAP antagonist is in Formula 4,
  • Y is -NR 6 R 7 ;
  • n 1;
  • R 1 is hydrogen or methyl
  • R 2 is methyl
  • R 3 is t-butyl
  • R 4 and R 5 are each independently hydrogen or methoxy
  • R 6 is hydrogen or methyl
  • R 7 is -(CH 2 ) l -C 3-6 cycloalkyl, where l is an integer from 0 to 3;
  • R 7 may be optionally substituted with one or more substituents selected from the group consisting of halogen and -CF 3 .
  • the IAP antagonist is in formula 4.
  • Y is 3-chloro-2,4-difluoroaniline
  • n 1;
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is t-butyl
  • R 5 may be methoxy.
  • the IAP antagonist is any one selected from the compound of Formula 4, stereoisomers, tautomers, solvates, and combinations thereof,
  • the FLT3 inhibitor may be any one selected from the compound of Formula 1, stereoisomers, tautomers, and combinations thereof.
  • the IAP antagonist is any one selected from the compound of Formula 4, stereoisomers, tautomers, and combinations thereof,
  • FLT3 inhibitors are 5-chloro-N-(3-cyclopropyl-5-(((3R, 5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H -Indol-3-yl)pyrimidin-2-amine, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
  • a FLT3 inhibitor, or any pharmaceutically acceptable salt or hydrate thereof, and an IAP antagonist, or a pharmaceutically acceptable salt or hydrate thereof, as an active ingredient wherein the IAP antagonist is (S )-N-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yl)-1-((S)-3,3-dimethyl-2- ((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
  • the IAP antagonist is (S )-N-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yl)-1-((S)-3,3-dimethyl-2- ((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-car
  • IAP antagonists are (S)-N-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yl)-1-((S)-3,3 -Dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide, a pharmaceutically acceptable salt thereof, or a hydrate thereof,
  • the FLT3 inhibitor may be any one selected from the compound of Formula 1, stereoisomers, tautomers, and combinations thereof.
  • the IAP antagonist is (S)-N-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yl)-1-((S )-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide, a pharmaceutically acceptable salt thereof, or a hydrate thereof ,
  • FLT3 inhibitors are 5-chloro-N-(3-cyclopropyl-5-(((3R, 5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H -Indol-3-yl)pyrimidin-2-amine, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
  • the IAP antagonist is a compound having IAP inhibitory activity described in Korean Patent Application Publication No. 10-2013-0121092 or International Patent Application Publication No. WO2012-030160, more specifically listed in Table 3 below. It may be a compound selected from the group consisting of a compound, or any pharmaceutically acceptable salt or hydrate thereof.
  • the IAP antagonist is (S)-N-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yl)-1-((S )-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt or hydrate thereof have.
  • 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4- (6-methyl-1H-indol-3-yl)pyrimidin-2-amine inhibits kinases such as SYK, which are known to be associated with AML resistance.
  • SYK kinase transcribed FLT3 by direct physical interaction is important for the development of FLT3-ITD-induced bone marrow dysplasia, and is primarily activated more in FLT3-ITD positive AML. Therefore, activation of other signaling pathways of kinases such as SYK may cause resistance in the treatment of AML patients.
  • the FLT3 inhibitor has a high risk of recurrence after treatment, has a poor prognosis, and reduces overall survival, against acute myelogenous leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutation.
  • AML acute myelogenous leukemia
  • FLT3 FMS-like tyrosine kinase 3
  • the FLT3 inhibitor according to the above embodiment exhibits clinical benefits in patients with acute myeloid leukemia (AML) who are resistant to conventional treatments.
  • AML acute myeloid leukemia
  • activated mutations in FLT3's internal tandem duplication (ITD) and tyrosine kinase domain (TKD) point mutations are reported as oncogenic driver mutations.
  • the mutation of TKD may be one that further includes internal tandem duplication (ITD).
  • the acute myelogenous leukemia to be treated using the pharmaceutical composition may be an acute myelogenous leukemia having a FLT3 mutation.
  • the acute myelogenous leukemia may have a mutation in the tyrosine kinase domain (TKD) (FLT3-TKD) of the FLT3 amino acid sequence.
  • the FLT3-TKD mutation may further include internal tandem duplication (ITD).
  • the FLT3-TKD mutation includes any one selected from FLT3 (D835Y), FLT3 (F691L), FLT3 (F691L/D835Y), FLT3 (ITD/D835Y), FLT3 (ITD/F691L), and combinations thereof. I can.
  • a pharmaceutical composition comprising a FLT3 inhibitor, a pharmaceutically acceptable salt thereof, or a solvate thereof, and an IAP antagonist, a pharmaceutically acceptable salt, or a solvate thereof, to be administered in combination according to one embodiment has a FLT3 mutation.
  • the acute myelogenous leukemia may be a mutant FLT3 polynucleotide-positive acute myelogenous leukemia, an internal tandem duplication (ITD) positive acute myelogenous leukemia, or an acute myelogenous leukemia with a FLT3 point mutation.
  • ITD internal tandem duplication
  • the acute myelogenous leukemia (AML) comprising a compound of Formula 1, or a pharmaceutically acceptable salt, or a FLT3 inhibitor of any one of a solvate thereof
  • AML acute myelogenous leukemia
  • the acute myelogenous leukemia (AML ) May have a mutation in the tyrosine kinase domain (TKD) (FLT3-TKD) of the FLT3 amino acid sequence.
  • TKD tyrosine kinase domain
  • the FLT3-TKD mutation may further include internal tandem duplication (ITD).
  • ITD internal tandem duplication
  • the FLT3-TKD mutation is any selected from FLT3 (D835Y), FLT3 (F691L), FLT3 (F691L/D835Y), FLT3 (ITD/D835Y), FLT3 (ITD/F691L), and combinations thereof It may contain one.
  • the FLT3 inhibitor is 5-chloro-N-(3-cyclopropyl-5-(((3R, 5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4- (6-methyl-1H-indol-3-yl)pyrimidin-2-amine, or a pharmaceutically acceptable salt or hydrate thereof.
  • the pharmaceutical composition according to one embodiment is an acute myelogenous leukemia (AML) having a FLT3 mutation, such as an internal tandem duplication (ITD) of FLT3 and a tyrosine kinase domain (TKD) point mutation, for example FLT3 inhibitors for the treatment of acute myeloid leukemia (AML) with FLT3 (ITD/D835Y) and FLT3 (ITD/F691L) mutations, or any pharmaceutically acceptable salt or hydrate thereof.
  • AML acute myelogenous leukemia
  • FLT3 mutation such as an internal tandem duplication (ITD) of FLT3 and a tyrosine kinase domain (TKD) point mutation
  • FLT3 inhibitors for the treatment of acute myeloid leukemia (AML) with FLT3 (ITD/D835Y) and FLT3 (ITD/F691L) mutations or any pharmaceutically acceptable salt or hydrate thereof.
  • the mutation of FLT3-TKD may include one or a plurality of amino acid mutations in the region of positions 823 to 861 of the FLT3 amino acid sequence.
  • the mutation of TKD may include a mutation of at least one amino acid selected from the group consisting of Nos. 835, 836, and 842 of the FLT3 amino acid sequence.
  • the mutation of TKD may include a mutation of amino acid No. 835 of the FLT3 amino acid sequence.
  • the mutation of TKD may be one in which aspartic acid No. 835 of the FLT3 amino acid sequence is substituted with valine, tyrosine, histidine, glutamic acid, or asparagine.
  • the mutation of TKD may be that isoleucine at No. 836 of the FLT3 amino acid sequence is substituted with leucine or aspartic acid.
  • the mutation of TKD may be a substitution of cysteine or histidine for tyrosine 842 of the FLT3 amino acid sequence.
  • the mutation may be FLT3 (D835Y).
  • the mutation of FLT3-TKD may have a mutation of at least one amino acid selected from the group consisting of Nos. 621, 627, 676, 691, and 697 of the FLT3 amino acid sequence.
  • the mutation of TKD may be a substitution of leucine for phenylalanine 691 of the FLT3 amino acid sequence.
  • the mutation may be FLT3 (F691L).
  • the mutation of the TKD may be one that further includes an intra-gene sequence overlap (ITD).
  • the mutation may be FLT3 (ITD/D835Y) or FLT3 (ITD/F691L).
  • FLT3 inhibitor As the FLT3 inhibitor according to an embodiment, 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4- (6-methyl-1H-indol-3-yl)pyrimidin-2-amine is caused by the FLT3 mutation in an in vivo study using Ba/F3 cells expressed in the FLT3 ITD/F691L or FLT3 ITD/D835Y xenograft mouse model. Resistance to overcome and treatment effect is verified.
  • the FLT3 inhibitor exhibits an effect of overcoming the resistance of acute myelogenous leukemia (AML) treatment.
  • the FLT3 inhibitor exhibits inhibitory activity against drug-resistant point mutant species (D835Y, F691L, or F691L/D835Y) of FLT3 due to the D835Y and F691L point mutations obtained in FLT3-TKD.
  • the mutation of TKD may be one in which aspartic acid No. 835 of the FLT3 amino acid sequence is substituted with tyrosine.
  • the mutation may be FLT3 (D835Y), or FLT3 (ITD/D835Y).
  • the mutation of TKD may be a substitution of leucine for phenylalanine 691 of the FLT3 amino acid sequence.
  • the mutation may be FLT3 (F691L) or FLT3 (ITD/F691L).
  • the FLT3 inhibitor according to the above embodiment is a result of performing an in vitro site-directed competition binding assay using an AML-resistant cell line, standard proliferation assay, immunoblotting, and apoptosis analysis. Through this, the treatment effect and overcoming resistance due to the FLT3 mutation are verified.
  • the FLT3 inhibitor according to the above embodiment strongly inhibits FLT3 (ITD/D835Y) and FLT3 (ITD/F691L) mutations in preclinical evaluation.
  • the FLT3 inhibitor according to the above embodiment exhibits high in vitro binding affinity in both mutations, in vitro and in vivo using Ba/F3 cell lines expressing FLT3 (ITD/D835Y) or FLT3 (ITD/F691L). Shows strong inhibitory activity.
  • the FLT3 inhibitor according to the above embodiment can exhibit high cytotoxic efficacy in MOLM-14 cell lines containing FLT3 ITD and overcome FL-induced drug resistance.
  • the FLT3 inhibitor according to the above embodiment can strongly inhibit the phosphorylation of SYK, STAT3 and STAT5 in KG-la cells.
  • the FLT3 inhibitor, or a pharmaceutically acceptable salt or solvate thereof is administered simultaneously, sequentially, in reverse order, or separately with the IAP antagonist, or a pharmaceutically acceptable salt or solvate thereof.
  • I can.
  • the route of administration includes, but is not limited to, oral, intravenous, intraarterial, intraperitoneal, intradermal, transdermal, intrathecal (intrathecal), intramuscular, intranasal, transmucosal, subcutaneous and rectal administration. Does not.
  • Formulations for administration are oral formulations such as tablets, powders, granules, capsules, suspensions, emulsions, syrups and aerosols, external preparations such as ointments, creams, injections, suppositories and sterile injections according to a conventional method. It can be formulated and used in any suitable form, including solutions.
  • FLT3 inhibitor As the FLT3 inhibitor according to an embodiment, 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4- (6-methyl-1H-indol-3-yl)pyrimidin-2-amine, or any pharmaceutically acceptable salt or hydrate thereof, can be administered orally.
  • (S)-N-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yl)-1-(( S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide, can be administered orally or by injection.
  • the FLT3 inhibitor, or a pharmaceutically acceptable salt or solvate thereof, and an IAP antagonist, or a pharmaceutically acceptable salt or solvate thereof may be included in a therapeutically effective amount, respectively.
  • AML acute myelogenous leukemia
  • the FLT3 inhibitor may be administered in an amount of 0.01 to 3000 mg, such as 0.1 to 1000 mg or 6 mg to 600 mg.
  • the FLT3 inhibitor is an amount of 0.001 to 200 mg/kg body weight, such as an amount of 0.05 to 100 mg/kg body weight, an amount of 0.1 to 50 mg/kg body weight, or an amount of 0.1 mg/kg to 10 mg/kg body weight It can be administered as.
  • the FLT3 inhibitor may be administered in an amount of 0.001 to 200 mg/kg body weight/day dose, such as 0.05 to 50 mg/kg body weight/day dose or 0.1 mg to 10 mg/kg body weight/day dose.
  • the FLT3 inhibitor may be administered in an amount of 0.01 mg/m 2 to 1000 mg/m 2 of body surface area, for example, 3.7 mg/m 2 to 370 mg/m 2 of body surface area.
  • the IAP antagonist may be administered in an amount of 0.1 to 2000 mg, such as 1 to 1500 mg, or 12 mg to 1200 mg.
  • the IAP antagonist may be administered in an amount of 0.01 to 400 mg/kg body weight, for example, 0.2 mg/kg to 200 mg/kg body weight.
  • the IAP antagonist may be administered in an amount of 0.01 to 300 body weight/day dose, such as 0.2 mg to 200 mg/kg body weight/day dose.
  • the IAP antagonist may be administered in an amount of 0.01 mg/m 2 to 1000 mg/m 2 of a body surface area, for example, 7.4 mg/m 2 to 740 mg/m 2 of a body surface area.
  • the dosage of the pharmaceutical combination according to one embodiment, or the dosage or therapeutically effective amount of the FLT3 inhibitor and the IAP antagonist in the combination may vary within wide tolerances and may be determined in a manner known in the art.
  • the dosage will be tailored to the individual requirements of each particular case, including the patient to be treated as well as the specific compound to be administered, the route of administration (oral, parenteral), and the condition to be treated.
  • the amount of the combined two drugs administered to a patient can be determined by the attending physician as a person skilled in the art by using known techniques and by observing the results obtained under similar circumstances.
  • the effective amount or dose of the compound to be administered the species of the mammal; Its size, age and overall health; Specific neoplasms involved; The degree or involvement or severity of the neoplasm; Individual patient response; The specific compound being administered; Mode of administration; Bioavailability characteristics of the administered formulation; The usage chosen; The use of concomitant drugs; And other relevant circumstances, a number of factors are considered by the attending diagnostician.
  • the daily dose when administered orally, may be about 0.001 to about 100 mg/kg per patient's body weight, for example, about 0.005 to about 30 mg/kg, for example about 0.01 to about 10 mg/kg. have.
  • the daily dose When administered intravenously, may suitably be about 0.0001 to about 10 mg/kg per body weight of the patient, and the whole is administered in divided doses of one or more doses per day.
  • the transmucosal oil formulation is administered at a dose of about 0.001 to about 100 mg/kg per body weight, and may be administered once a day or dividedly administered several times a day.
  • the daily dose may be administered as a single dose or divided doses, or may be given as a continuous infusion for parenteral administration.
  • the FLT3 inhibitor and the IAP antagonist may be administered simultaneously, sequentially or separately without specific time restrictions.
  • This administration here is meant to provide a therapeutically effective level of the two compounds in the patient's body.
  • the inter-administration interval may be several seconds, several minutes, several hours, or days of a predetermined interval, and may have a pause as necessary.
  • composition refers to a mixture comprising a compound disclosed herein and at least one and optionally more than one other pharmaceutically acceptable chemical component, such as a pharmaceutically acceptable additive. Means.
  • the pharmaceutical composition may further include one or more optional pharmaceutically acceptable additives selected from the group consisting of excipients, binders, disintegrants, lubricants, and any combination thereof.
  • the additives are any substances known to those skilled in the art to be useful in the preparation of formulations, and can be adjusted as necessary, for example, according to the mode of administration of the drug.
  • Another aspect of the present invention is a FLT3 inhibitor, or any pharmaceutically acceptable salt or hydrate thereof, and an IAP antagonist, or any pharmaceutically acceptable salt or hydrate thereof, as a drug for the treatment of acute myelogenous leukemia (AML).
  • AML acute myelogenous leukemia
  • the term “combination” or “pharmaceutical combination” as used herein refers to a product produced from mixing or combining two or more active ingredients, and includes both fixed and non-fixed combinations of active ingredients.
  • the term “fixed combination” means that the active ingredient, eg, a compound disclosed herein and one or more additional therapeutic agents, are administered to a subject simultaneously in the form of a single aggregate or dosage.
  • the term “unfixed combination” means that the active ingredient, eg, a compound disclosed herein and one or more additional therapeutic agents, are administered to a subject as separate aggregates simultaneously, simultaneously or sequentially without specific time limitations, Here, such administration provides a therapeutically effective level of the active ingredient in the body of the subject.
  • cocktail therapy for example the administration of three or more active ingredients.
  • Another aspect of the present invention provides a pharmaceutical kit, wherein the pharmaceutical compositions are administered simultaneously, sequentially, in reverse order or separately.
  • Another aspect of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising an IAP antagonist, or a pharmaceutically acceptable salt or solvate thereof, an Fms-like tyrosine kinase-3 (FLT3) inhibitor, or a medicament thereof It provides a pharmaceutical composition for the treatment of acute myelogenous leukemia (AML), which is administered in combination with a scientifically acceptable salt or solvate.
  • AML acute myelogenous leukemia
  • the FLT3 inhibitor may be a compound selected from the compound of Formula 1, a stereoisomer thereof, a tautomer, and a combination thereof.
  • the FLT3 inhibitor may be a compound selected from a compound represented by Formula 3 below, a stereoisomer thereof, a tautomer, and a combination thereof.
  • the IAP antagonist may be a compound selected from the compound of Formula 4, stereoisomers, tautomers, and combinations thereof.
  • an Fms-like tyrosine kinase-3 (FLT3) inhibitor or any pharmaceutically acceptable salt or hydrate thereof
  • an IAP antagonist or any pharmaceutically acceptable salt or hydrate thereof
  • the active ingredients are administered at the same time, sequentially, in reverse order or individually, providing a pharmaceutical combination for the treatment of acute myelogenous leukemia (AML).
  • AML acute myelogenous leukemia
  • Another aspect of the present invention provides a method of treating acute myelogenous leukemia (AML), wherein the method comprises administering the following active ingredients simultaneously, sequentially, in reverse order, or separately. :
  • FLT3 Fms-like tyrosine kinase-3
  • Another aspect of the present invention is a method of treating acute myelogenous leukemia (AML) in a patient, the method comprising the steps of simultaneously, sequentially, reversely or individually administering the following active ingredients. , Provide treatment methods:
  • the patient is administered an IAP antagonist, or any pharmaceutically acceptable salt or hydrate thereof.
  • steps (a) and (b) may be under the direction or control of a doctor.
  • Another aspect of the present invention provides a method of treating acute myelogenous leukemia (AML) in a patient, wherein the method comprises the following steps simultaneously, sequentially, in reverse order or separately:
  • an Fms-like tyrosine kinase-3 (FLT3) inhibitor or any pharmaceutically acceptable salt or hydrate thereof, and an IAP antagonist, or any pharmaceutically acceptable salt thereof, or It includes a hydrate as an active ingredient, wherein the two active ingredients are administered simultaneously, sequentially or separately, providing a pharmaceutical combination for the treatment of acute myelogenous leukemia (AML).
  • FLT3 Fms-like tyrosine kinase-3
  • IAP antagonist or any pharmaceutically acceptable salt thereof, or It includes a hydrate as an active ingredient, wherein the two active ingredients are administered simultaneously, sequentially or separately, providing a pharmaceutical combination for the treatment of acute myelogenous leukemia (AML).
  • AML acute myelogenous leukemia
  • One embodiment provides a pharmaceutical combination comprising an FLT3 inhibitor, or any pharmaceutically acceptable salt or hydrate thereof, and an IAP antagonist, or any pharmaceutically acceptable salt or hydrate thereof.
  • the combination according to one embodiment includes the FLT3 inhibitor and the IAP antagonist in the form of a salt or hydrate formed from two components. For example, the formation of the salt may be partially or completely.
  • Another aspect of the present invention provides a pharmaceutical combination comprising an FLT3 inhibitor, or any pharmaceutically acceptable salt or hydrate thereof, and an IAP antagonist, or any pharmaceutically acceptable salt or hydrate thereof.
  • the combination according to one aspect contains the FLT3 inhibitor and the IAP antagonist in the form of a salt or hydrate formed from the two components. For example, the formation of the salt may be partially or completely.
  • Another aspect of the present invention is acute myelogenous using a composition comprising an FLT3 inhibitor, or any pharmaceutically acceptable salt or hydrate thereof, and an IAP antagonist, or any pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
  • a method of treating a subject suffering from leukemia (AML) is provided.
  • the two active ingredients may be administered simultaneously, sequentially or separately.
  • the treatment method according to an embodiment provides a treatment method for acute myelogenous leukemia having FLT3 mutation using the composition.
  • Another aspect of the present invention is a FLT3 inhibitor, or any pharmaceutically acceptable salt or hydrate thereof, used in the manufacture of a drug for treating acute myelogenous leukemia (AML), and an IAP antagonist, or any pharmaceutically thereof. It provides the use of a combination comprising an acceptable salt or hydrate as an active ingredient.
  • Combination therapy of a FLT3 inhibitor and an IAP antagonist using the combination of one aspect according to the present invention has an improved therapeutic effect compared to the effect of administration of the FLT3 inhibitor or the IAP antagonist alone.
  • the therapeutic effect using the combination according to an embodiment shows a synergistic therapeutic effect of more than the arithmetic sum of two or more drugs in combination.
  • subject encompasses mammals and non-mammals, including humans.
  • mammals include humans, chimpanzees, apes, monkeys, cows, horses, sheep, goats, pigs; Includes, but is not limited to, rabbits, dogs, cats, rats, mice, guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish, and the like.
  • treating include limiting, delaying, arresting, reducing or reversing the progression or severity of an existing symptom, disease, condition or disease. do.
  • to refers to a range including numerical values described before and after the term “to” as a lower limit and an upper limit, respectively. It means the interval between the above-mentioned values, including the values described before and after.
  • the numerical value may be a range selected and combined with any number of upper and/or lower limits.
  • FLT3 inhibitor 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H -Indol-3-yl)pyrimidin-2-amine (hereinafter Compound A) and IAP antagonist (S)-N-(4-(3-chloro-2,4-difluorophenylamino)-7-me Toxiquinazolin-6-yl)-1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxe It was observed whether MOLM-13 (DSMZ no.
  • MOLM-13 was diluted with a culture medium to 8000 nM, which is a concentration (GI 40 ) that inhibits the growth of about 40%, and was cultured for 3 days after simultaneous treatment with Compound A or treatment alone.
  • CCG CellTiter-Glo® assay was performed to measure the viability of cells, and a 50% growth inhibition value (GI 50 ) for cell growth for the result analysis was calculated using GraphPad Prism software. The results are shown in Table 4 and FIGS. 1 and 2.
  • Table 4 below shows data on MOLM-13 cell growth inhibitory activity by compound A alone or in combination treatment.
  • the Y-axis represents the cell growth rate (%), and the X-axis represents the logarithmic concentration of Compound A (the logarithmic value of the concentration value in nM).
  • Figure 2 shows the degree of inhibition of cell growth when compound A (FLT3 inhibitor) 2.5 nM, IAP antagonist 8000 nM, or Compound A 2.5 nM and IAP antagonist 8000 nM are used in combination. Represents.
  • the MOLM-13-Luc2 cell line was injected into the tail vein of NOG mice at 1 ⁇ 10 7 cells/0.1 mL/mouse (tail-vein injection).
  • Bioluminescence images of MOLM-13-Luc2 cells were measured with a Lumina III IVIS imaging system (PerkinElmer) and quantified using Living Image software (PerkinElmer). During the measurement, mice were injected with D-luciferin intraperitoneally, and imaged under anesthesia using isoflurane. Images were measured for the first grouping during the experiment, and then measured on a specific day according to the test purpose.
  • the IAP antagonist was administered orally once a day at a dose of 100 mg/kg/day.
  • Compound A was administered orally once a day at a dose of 10 mg/kg/day, and the IAP antagonist was orally administered once a day at a dose of 100 mg/kg/day.
  • all subjects in each group received individual medications until the time of death.
  • FIG. 3 shows the anti-tumor effect when administered in combination with a compound A and an IAP antagonist in nude mice xenografted with MOLM-13-Luc2 cell line.
  • the Y-axis represents the percentage of surviving mice in each experimental group (survival rate) (%), and the X-axis represents the number of days of administration.
  • the median survival period and the total survival period in the combination group were 29 days and 32 days, respectively.
  • the result was a value increased than the median survival time (9 days) and overall survival (11 days) in the IAP antagonist administration group, and the median survival time (21 days) in the compound A administration group It was an increased value than the overall survival period (23 days).
  • the FLT3 inhibitor 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4- (6-methyl-1H-indol-3-yl)pyrimidin-2-amine and IAP antagonist (S)-N-(4-(3-chloro-2,4-difluorophenylamino)-7- Methoxyquinazolin-6-yl)-1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-ca It can be seen that an improved antitumor effect is exhibited by combining the boxamide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique pour le traitement de la leucémie myéloïde aiguë (LMA) et une méthode de traitement de la leucémie myéloïde aiguë à l'aide de celle-ci, la combinaison comprenant un inhibiteur de tyrosine kinase-3 de type Fms (FLT3) ou un sel ou un solvate pharmaceutiquemnt acceptable de celui-ci, et un antagoniste contre un inhibiteur de la protéine de l'apoptose (IAP) ou un sel ou un solvate pharmaceutiquemnt acceptable de celui-ci en tant que combinaison thérapeutiquement efficace.
PCT/KR2020/002541 2019-02-22 2020-02-21 Combinaison pharmaceutique comprenant un inhibiteur flt3 et un antagoniste iap pour le traitement de la leucémie myéloïde aiguë WO2020171649A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2019-0021227 2019-02-22
KR20190021227 2019-02-22
KR10-2020-0021501 2020-02-21
KR1020200021501A KR20200102948A (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물

Publications (1)

Publication Number Publication Date
WO2020171649A1 true WO2020171649A1 (fr) 2020-08-27

Family

ID=72144957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/002541 WO2020171649A1 (fr) 2019-02-22 2020-02-21 Combinaison pharmaceutique comprenant un inhibiteur flt3 et un antagoniste iap pour le traitement de la leucémie myéloïde aiguë

Country Status (1)

Country Link
WO (1) WO2020171649A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027966A1 (fr) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3
WO2023129667A1 (fr) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Composés pyrazines utilisés comme inhibiteurs de flt3
WO2023225005A1 (fr) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Polythérapie à base de flt3 pour le cancer et compositions associées

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318446A1 (en) * 2005-01-11 2009-12-24 Cyclacel Limited 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy
US20110015173A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
KR101560227B1 (ko) * 2010-08-31 2015-10-14 한미사이언스 주식회사 세포사멸 유도 활성을 갖는 퀴놀린 또는 퀴나졸린 유도체
KR20180088317A (ko) * 2017-01-26 2018-08-03 한미약품 주식회사 피리미딘 화합물 및 그의 의약 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318446A1 (en) * 2005-01-11 2009-12-24 Cyclacel Limited 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
US20110015173A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
KR101560227B1 (ko) * 2010-08-31 2015-10-14 한미사이언스 주식회사 세포사멸 유도 활성을 갖는 퀴놀린 또는 퀴나졸린 유도체
KR20180088317A (ko) * 2017-01-26 2018-08-03 한미약품 주식회사 피리미딘 화합물 및 그의 의약 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHOU, JIANBIAO, CHNG WEE-JOO: "Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies", WORLD J. CLIN ONCOL., vol. 9, no. 5, 14 September 2018 (2018-09-14), pages 90 - 97, XP055732807, DOI: 10.5306/wjco.v9.i5.90 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027966A1 (fr) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3
WO2023129667A1 (fr) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Composés pyrazines utilisés comme inhibiteurs de flt3
WO2023225005A1 (fr) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Polythérapie à base de flt3 pour le cancer et compositions associées

Similar Documents

Publication Publication Date Title
WO2020171649A1 (fr) Combinaison pharmaceutique comprenant un inhibiteur flt3 et un antagoniste iap pour le traitement de la leucémie myéloïde aiguë
WO2020171646A1 (fr) Composition pharmaceutique comprenant un inhibiteur flt3 et un agent hypométhylant pour le traitement de la leucémie myéloïde aiguë
WO2020262974A1 (fr) Composition pharmaceutique pour le traitement de la leucémie myéloïde aiguë contenant un inhibiteur de flt3 et des agents de chimiothérapie
WO2010104306A2 (fr) Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
WO2019088677A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la leucémie myéloïde aiguë ou du cancer du sein métastatique
TW201004955A (en) Pyridopyridone derivatives, preparation thereof and therapeutic use thereof
WO2021167389A1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un inhibiteur de signalisation mtor comme principe actif
WO2020235902A1 (fr) Dérivé de pyrimidine condensé avec un hétérocycle et son utilisation
TW202220994A (zh) 雙環化合物，包含其的藥物組合物及其用途
WO2021230600A1 (fr) Composition anticancéreuse comprenant un médicament anticancéreux métabolique
WO2021215765A1 (fr) Dérivé de 3-azabicycloalkyle et composition pharmaceutique le contenant
WO2023014006A1 (fr) Composé pour la dégradation ciblée de ras
WO2018030800A1 (fr) Composé d'urée ayant un squelette de 3,4-dihydropyrimido [4,5-d] pyrimidine -2 (1h)-one ayant une activité d'inhibition de protéine kinase
WO2021066443A1 (fr) Composition pharmaceutique pour le traitement de la leucémie aiguë myéloïde contenant un inhibiteur de flt3 et un inhibiteur de mdm2
WO2019231261A1 (fr) Nouveau composé dérivé de biphényle et utilisation associée
WO2021085888A1 (fr) Nouveau dérivé de pyrimidine à substitution hétérocyclique présentant un effet inhibiteur de la croissance des cellules cancéreuses, et composition pharmaceutique le contenant
KR20200102948A (ko) Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
WO2021182903A1 (fr) Composition comprenant un inhibiteur de kinase pi3 et un inhibiteur de btk
WO2019035522A1 (fr) Composition pour prévenir ou traiter le cancer, contenant un dérivé à base de triazolopyridine comme principe actif
CN101227909A (zh) 包含嘧啶基氨基苯甲酰胺化合物和Flt-3抑制剂用于治疗增殖性疾病的组合
WO2018101762A1 (fr) Composition pharmaceutique de prévention ou de traitement d'une lésion rénale aiguë ischémique, comprenant un dérivé tricyclique ou un sel pharmaceutiquement acceptable de ce dernier
WO2019112381A1 (fr) Composition comprenant un inhibiteur de kinase pi3 et un inhibiteur de bcl-2
WO2021133037A1 (fr) Dérivé de pyrrolidine et composition pharmaceutique de prévention ou de traitement de maladies associées à la protéine bêta-amyloïde ou tau contenant ce dernier
CN101489552A (zh) 三氟甲基取代的苯甲酰胺类在治疗神经学障碍中的用途
EP3386988A1 (fr) Nouveaux dérivés de la dihydropyranopyrimidinone et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20758618

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20758618

Country of ref document: EP

Kind code of ref document: A1